Recent Updates
Recently added Catalysts

Crohn's Disease: 4 biotech companies with clinical-stage programmes

Immunology & InflammationOrphan cornerData as of 2026-09-04

Competitors4in the clinic
Median market cap$714Muniverse median $1.20B
Allocated capital$5.1B$11.7B competing
Phase 3 or filed03 mid, 1 early
Pure plays3this indication only
Capital rank37/299crowding rank 45

Crohn's Disease sits in the orphan corner of the map: 4 developers, none of them large, with a median market cap of $714M against a $1.20B universe median.

A thin field of small caps usually means a narrow addressable population, so the whole field can be repriced by one readout or one financing.

ABVX alone accounts for 85% of the $11.7B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$5.1B of allocated capital sits in Crohn's Disease, 37th of 299 indications, and 3 of the 4 companies are pure plays that trade on this indication alone.

Companies developing drugs for Crohn's Disease 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ABVXAbivaxObefazimodPhase 21$9.9BNo3 31 Dec 2026
AGMBAgomAb Therapeutics NVOntunisertibPhase 22$730MYes1 31 Dec 2026
STTKShattuck LabsSL-325Phase 21$699MYes1 30 Jun 2028
PALIPalisade BioPALI-2108Phase 11$356MYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. ABVX holds 85% of the $11.7B competing in this indication.

Why Crohn's Disease is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Crohn's Disease has 4 competitors and a median of $714M.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Androgenetic Alopecia2 companies · $5.6B · median $2.8BConcentrated betSjögren's Disease4 companies · $4.4B · median $1.7BConcentrated betIdiopathic Pulmonary Fibrosis7 companies · $5.8B · median $1.3BGold rushThyroid Eye Disease2 companies · $3.6B · median $2.8BConcentrated betIgA Nephropathy4 companies · $3.6B · median $1.8BConcentrated betSystemic Lupus Erythematosus13 companies · $7.2B · median $1.2BKnife fightWarm Autoimmune Hemolytic Anemia2 companies · $2.4B · median $3.8BConcentrated betAlopecia Areata3 companies · $2.2B · median $1.6BConcentrated bet

Crohn's Disease pipeline questions

Which biotech companies are developing drugs for Crohn's Disease?

Abivax (ABVX, Obefazimod, Phase 2); AgomAb Therapeutics NV (AGMB, Ontunisertib, Phase 2); Shattuck Labs (STTK, SL-325, Phase 2); Palisade Bio (PALI, PALI-2108, Phase 1). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Crohn's Disease.

How advanced is the Crohn's Disease pipeline?

Of the 4 clinical-stage programmes in Crohn's Disease, 0 are in Phase 3 or filed, 3 are in mid-stage development and 1 is in early-stage development.

Which company leads the Crohn's Disease field?

ABVX is the largest developer in Crohn's Disease, holding 85% of the $11.7B of market capitalisation competing in the indication. The median competitor is worth $714M.

When is the next Crohn's Disease catalyst?

The next dated catalyst in Crohn's Disease is ABVX on 31 Dec 2026. 3 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map